CHMP recommends EU approval of Cytokinetics' MYQORZO for obstructive HCM

CYTOKINETICS INC

CHMP adopted positive opinion recommending EU marketing authorization for MYQORZO (aficamten).
Indicated for symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy in adults.
European Commission final decision expected in Q1 2026.
MYQORZO is a cardiac myosin inhibitor.

item 8.01

CYTOKINETICS INC filing history →

Source: SEC EDGAR

accession 0001193125-25-316904

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.